Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
Goldman also slashes its one-year price target by nearly two-thirds on expectations that Nektar's in-the-works cancer treatment won't generate revenue anytime soon.
Let's check and see if the charts and indicators suggest where prices might bottom out.
Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.
The technical pattern of the indices actually looks quite promising, but under the surface is a different story.
Cigna shares rose after being upgraded to outperform by analysts at BMO Capital.
Analysts at Stifel raise their price target on the stock to $95.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.